Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 11:13 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Acceleron Pharma, a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).

    article source